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Background: HIV infection induces chronic immune activation which is associated with accelerated disease
progression; the causes of this activation, however, are incompletely understood. We investigated the activation
status of CD4+ T cells specific for chronic herpes viruses and the non-persistent antigen tetanus toxoid (TT) in HIV
positive and HIV negative donors to assess whether persistent infections contribute to chronic CD4+ T cell
activation.
Methods: Untreated HIV+ patients and healthy, aged matched controls were recruited and activation levels
assessed and compared between cells specific for persistent and non-persistent antigens. Activation levels on
antigen-specific CD4+ T cells were measured by intracellular cytokine staining following in vitro stimulation with
various recall antigens (CMV, EBV, HSV, VZV and TT) in conjunction with cell surface phenotyping.
Results: Activation levels of herpes virus-specific CD4+ T cell populations, assessed by co-expression of CD38 and
HLA-DR, were significantly elevated in HIV+ individuals compared to normal controls and compared to TT-specific
responses. In contrast, we found similar levels of activation of TT-specific CD4+ T cells in HIV+ and HIV- donors.
Conclusions: These results show a disparate distribution of immune activation within CD4+ T cell populations
depending on their specificity and suggest that the elevated level of immune activation that characterizes chronic
HIV infection may be influenced by the persistence of other antigens.
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Chronic immune activation is a characteristic feature
of HIV-1 infection contributing to CD4+ T cell loss
and progression to AIDS and death [1-3]. In contrast,
SIV infection of natural primate hosts does not cause
chronic immune activation despite sustained systemic
viral replication and thus disease progression and im-
munodeficiency are largely absent [4-6]. Persistent im-
mune activation is characterized by elevated levels of
serum cytokines and chemokines [7-9], B cell dysregulation
(reviewed in [10]), interference with T cell homeosta-
sis [11,12] and lymphocyte activation, reflected by
expression of markers such as CD38 and HLA-DR
[3,13], increased in vivo turnover [14,15] and enhanced
spontaneous apoptosis [16]. Importantly, activation
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reproduction in any medium, provided the orinfection are strong predictors of disease progression
[3,17] and viral control [13], however the causes of this
activation are incompletely understood. Moreover, it
is likely that the activation of CD4+ and CD8+
lymphocytes are mediated by distinct processes [18,19].
The mechanisms leading to the activation and deple-
tion of CD4+ lymphocytes are of particular interest
since their maintenance is critical in staving off the
onset of AIDS.
It is clear that not only HIV-infected or HIV-
specific T cells exhibit increased levels of activation
and turn-over but also cells with other specificities
[20]. Activated CD4+ T cells also represent ideal
targets for productive HIV-infection, thereby fostering
an activation-infection-cascade. Recently, increased
levels of systemic lipopolysaccharide (LPS) and other
bacterial products, possibly caused by microbial trans-
location in the intestine, have been implicated in the
genesis of chronic immune activation in HIV-1 infection,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nition receptors (PRRs) and inflammatory cytokines
[21,22]. Although PRR- and cytokine-mediated bystander
activation independent of T cell receptor (TCR) triggering
might provide direct stimulation for memory cells [23-26],
a causal link between microbial translocation and TCR-
independent immune activation remains to be shown.
We have recently shown a correlation between HIV-
specific CD4+ T cell dynamics following HIV viral re-
bound, and CD4+ T cell dynamics specific for chronic
herpes viruses such as cytomegalovirus and Epstein-Barr
virus [27]. No correlation was demonstrated between the
HIV-specific response and responses to non-persistent
antigens. This may indicate that TCR-dependent signals
provided by low levels of persistent antigen derived from
herpesviruses may be involved in chronic T cell activa-
tion. In the current study, we extended these findings
and compared the activation status of CD4+ T cells spe-
cific for persistent herpes viruses, and for the non-per-
sistent antigen tetanus toxoid in patients with untreated
HIV infection and in healthy controls. While in
HIV-negative controls T cell specificity did not meas-
urably influence the level of immune activation, we
found significantly increased immune activation in
herpesvirus- but not TT-specific CD4+ T cell
populations of patients with untreated HIV-infection.
These results underscore our hypothesis that persist-
ent infections with herpesviruses substantially con-
tribute to chronic immune activation in HIV-1
infection.
Methods
Study subjects
Donors with chronic untreated HIV clade B infection,
detectable viral load (>5,000 copies/ml) and CD4+
counts >250/μl were recruited from the infectious
disease outpatient clinic of the University Hospital of
Zurich. Healthy, age-matched controls were likewise
recruited. Patients were pre-screened by IFNγ ELISpot
for antigen reactivity. The study protocol was
approved by the hospital ethics committee and writ-
ten informed consent was obtained according to the
guidelines of the University Hospital Zurich. See
Table 1 for detailed donor profiles.
Cell preparation and antigen stimulation
Approximately 80ml Ethylenediaminetetraacetic Acid
(EDTA)-anticoagulated blood was drawn from each
donor, and peripheral blood mononuclear cells
(PBMC) were extracted by density centrifugation
within 5 hours using Lymphocyte Separation Media
(PAA Laboratories, Austria). The extracted PBMC were
washed three times in 1× PBS (once at 300 × g and
twice at 100 × g to remove platelets), then resuspendedat 2 × 107 cells/ml in RPMI supplemented with 10%
foetal calf serum, 100 U/ml penicillin, 100 μg/ml
streptomycin and 2 mM L-glutamine (all PAA) (RF-10)
plus 20 μg/ml DNase (Roche, Germany).
Most samples were assayed with fresh PBMC, how-
ever for some samples, PBMC were cryopreserved.
For analyzing frozen samples, autologous monocyte-
derived dendritic cells (MDDCs) were prepared ap-
proximately 1 week prior to analysis. 10% MDDCs
were added to the thawed PBMC for analysis.
Antigen stimulations were performed using 2 × 106
cells in 96-well U-bottomed plates in a final volume
of 200 μl. Stimulations were performed with HIV
peptides (NIH AIDS Research & Reference Reagent
Program, 5 μg/ml/peptide), cytomegalovirus (CMV)
lysate (Virion, Germany; 50 g/ml), Epstein-Barr virus
(EBV) lysate (Virusys, USA; 18.75 μg/ml), Herpes
simplex virus-1 & -2 lysate (Virion, 18.75 μg/ml),
Varicella Zoster virus (VZV) lysate (Virion, 2.5 μg/ml)
and Tetanus Toxoid (Chiron, Germany; 31.1 μg/ml)
in conjunction with 0.5 μl each anti-CD28 (Becton
Dickinson, clone 28.2) and anti-CD49d (BD, clone
9F10). Cells were cultured at 37°C, 5% CO2 for 2 hours,
then 10 μg/ml Brefeldin A was added and cells cultured
for a further 4 hours at 37°C. Samples were then held at
4°C overnight.Intracellular cytokine staining and T cell phenotyping
Cells were surface stained with anti-CD3 Pacific Blue
(clone UCHT1), anti-CD45RA PE (clone HI100), anti-
CD4 PerCP (clone SK3), anti-CD38 APC (clone HIT2)
and anti-HLA-DR APC-H7 (clone L243), followed by
permeabilisation and intracellular staining with anti-
IFNγ PE-Cy7 (clone B27) (all from BD) and anti-IL-2
FITC (BioLegend, clone MQ1-17H12). Additional
phenotyping was perfomed using anti-PD-1 PE-Cy7
(BioLegend, clone EH12.2H7) and anti-β7 integrin
(eBioscience, clone FIB504). Samples were acquired
on a three-laser, 9- parameter LSR II Flow cytometer
(BD), and analysis performed using FlowJo v7.5.5
(Treestar, USA). Doublets were excluded using side-
and forward-scatter height and width parameters, and
CD4+CD45RA- and CD4+CD45RA+ lymphocytes analysed
for cytokine production and activation. Fluorescence
minus one controls were used to set gates for HLA-
DR, CD38, PD-1 and β7 integrin [28], and DMSO or
co-stimulation-only samples used to set gates for
cytokine production. Responses greater than or equal
to two times background were considered positive.Statistical analysis
Results were analysed and graphed using Prism v5.04
(GraphPad Software, USA). Unpaired, 2-tailed t tests and
Table 1 Donor profiles
Donor ID Gender Age HIV status RNA copies/ml CD4 cells/ul CD4 (%)
02RB M 56 positive 160000 326 21
09GH F 41 positive 64000 339 25
12VF M 38 positive 39000 398 17
13OJ M 42 positive 33000 426 31
19CT M 46 positive 140000 323 29
21JH M 40 positive 6800 293 28
23RB M 24 positive 110000 598 37
24BZ F 27 positive 34000 341 27
26PC M 40 positive 37000 440 35
27BS F 49 positive 26000 262 21
28JA M 58 positive 24000 650 25
31PO M 46 positive 130000 472 22
34GB M 28 positive 8100 482 25
35DS M 48 positive 6600 578 33
40TF M 53 positive 11000 793 27
05KC M 43 positive 35200 257 21
06MV F 58 positive 73000 596 27
11CS F 42 positive 19000 362 23
20YB M 47 positive 16200 722 30
M 74% Mean 43 Mean 27
F 26% SD 10 SD 5
HD01 F 32 negative 56
HD03 M 28 negative 39
HD05 F 29 negative 36
HD09 F 31 negative 48
HD11 F 27 negative 31
HD12 M 45 negative 39
HD13 M 59 negative 39
HD14 F 53 negative 48
HD15 F 52 negative 50
HD16 F 55 negative 54
M 30% Mean 41 Mean 44
F 70% SD 13 SD 8
Demographics, HIV status and CD4 profiles of study participants. M =male, F = female, SD = standard deviation.
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Correlation analysis used 2-tailed Pearson correlation.
Results
HIV+ donors show elevated levels of CD4+ T cell activation
Overall activation levels, evaluated by co-expression of
CD38 and HLA-DR, were compared on CD4+CD45RA+
(naïve and terminally differentiated) and CD4+CD45RA-
(antigen experienced) subsets in HIV+ and HIV- donors
(Figure 1). In HIV- donors, both populations had lowlevels of activation (CD4+CD45RA+: mean 0.47% CD38+
HLA-DR+; CD4+CD45RA-: mean 0.42% CD38+HLA-DR+).
As expected, the activation levels in the HIV+ donors were
significantly higher for both populations (CD4+CD45RA+:
mean 1.50%, p < 0.01; CD4+CD45RA-: mean 2.98%,
p < 0. 01). The activation level of the CD4+CD45RA- po-
pulation was significantly higher than the CD4+CD45RA+
population (p < 0.01), suggesting that antigen encounter
may influence activation levels in HIV+ individuals. While
CD38 and HLA-DR expression were significantly higher
Figure 1 Comparison of activation levels in CD4+ subsets
between HIV+ and HIV- donors. PBMC samples from 19 HIV+
and 10 HIV- donors were characterized by flow cytometry. The
CD3+CD4+CD45RA+ and CD3+CD4+CD45RA- populations were
assessed for expression of both CD38 and HLA-DR. Activation levels of
the CD4+ subsets from HIV+ donors (open symbols), and HIV- donors
(filled symbols) are shown. Box and whisker plots (in grey) extend from
the 5th to the 95th percentile, and the black line depicts the mean.
Unpaired 2-tailed t-tests were conducted to compare activation levels
between HIV+ and HIV- populations, and Mann–Whitney tests used to
compare levels within HIV+ or HIV- populations.
Figure 2 PD-1 expression within memory and activated
memory subsets. PBMC samples from a subset of HIV+ and HIV-
donors were assessed for PD-1 expression by flow cytometry. PD-1
expression in total memory (CD45RA-) and activated (CD38+HLA-DR+)
CD4+ T cells in HIV+ donors (open symbols), and HIV- donors (filled
symbols) are depicted. Box and whisker plots (in grey) extend from
the 5th to the 95th percentile, and the black line depicts the mean.
Unpaired 2-tailed t-tests were conducted to compare PD-1 levels
between HIV+ and HIV- populations, and Mann–Whitney tests used
to compare levels within HIV+ or HIV- populations.
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cells displayed an activated phenotype.
Activated CD4 T cells in HIV+ and HIV- donors express
PD-1 and are β7 integrin negative
To address whether CD4+ T cells with an activated phe-
notype defined by HLA-DR and CD38 co-expression
could be distinguished between HIV+ and HIV- indivi-
duals, we performed co-staining for PD-1 and integrin
β7. PD-1 is an activation marker associated with T cell
exhaustion in chronic viral infections [6,29] and is ex-
pressed on a large proportion of T cells specific for viru-
ses with a high level of persistence such as HIV, HBV
and HCV [14-16]. β7 is an integrin which marks T cells
with specific gut homing properties [17]. We chose these
two additional markers to evaluate the activation sta-
tus of the cells using an independent activation marker
(PD-1) and to assess whether CD4 T cell activation in
HIV patients might be disproportionally evident on cells
with gut-homing potential (α4β7), possibly as a conse-
quence of increased priming of microbiota-specific T
cells in the setting of increased gut permeability. We did
not find integrin β7 expression on HLA-DR and CD38
co-expressing cells from either HIV+ or HIV- donors
(data not shown, Additional file 1: Figure S1). PD-1 ex-
pression was elevated on CD38 and HLA-DR expressingcells compared to the bulk CD4+CD45RA- population in
both HIV+ and HIV- donors (Figure 2).
Magnitude and functionality of antigen-specific CD4+ T
cell responses in HIV+ and HIV- individuals
Following in vitro stimulation, we detected IL-2 and
IFNγ producing CD4+ T cell responses to a range of an-
tigens including persistent herpes viruses (CMV, EBV,
HSV, VZV) and a non-persistent bacterial vaccine an-
tigen (TT) (Figure 3). Responses to the viral antigens
included IL-2, IFNγ and dual-expressing cells, whereas
only IL-2 production was detected in response to TT.
While IL-2 responses to TT did not differ in HIV+ and
HIV- donors (p = 0.41), frequencies of herpes-virus spe-
cific IL-2 producing cells were generally higher in HIV-
donors, reaching statistical significance for CMV (p <
0.01), EBV (p = 0.05) and VZV (p = 0.04) (Figure 3). The
same trend was seen for HSV, although the difference
did not reach significance. In contrast, frequencies of
IFNγ-producing cells largely did not differ between HIV+
and HIV- donors with only CMV-specific IFNγ respon-
ses higher in HIV+ donors (p = 0.04) (EBV p = 0.87, HSV
p = 0.32, VZV p = 0.96, TT = not detected in either group).
Elevated activation levels of herpes-virus specific
responses in HIV+ donors
Next, we studied the extent of CD38 and HLA-DR co-
expression on the cytokine producing T cell populations.
Before doing so, we had to rule out that the short-term
antigen stimulation itself would induce any changes in
Figure 3 Antigen-specific cytokine responses detected to persistent herpes viruses and tetanus toxoid. Following a six hour stimulation,
PBMCs were assessed by intracellular cytokine staining for responses to HIV, herpes viruses CMV, EBV, HSV & VZV, and the bacterial antigen
tetanus toxoid. Responses were categorized according to the combination of cytokines produced (either IL-2 or IFNγ alone, or both together).
Cytokine responses for each antigen are shown with HIV- donors on the left and HIV+ donors on the right. Unpaired 2-tailed t-tests were used to
compare responses between HIV+ and HIV- donors.
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ted the fold change in CD38/HLA-DR co-expression
of SEB stimulated cultures compared to control cultures
and plotted these changes against the background level of
CD38 and HLA-DR expression. We found no correlation
(Additional file 2: Figure S2), and therefore concluded that
any change induced by the assay itself was minimal and
affected all samples to an equal extent.
When assessing CD38 and HLA-DR expression on cy-
tokine producing cells in HIV+ and HIV- responders, we
observed striking differences, with very few activated
cells detected in HIV- responders. Moreover, activation
levels were similar in herpesvirus- and TT-specific CD4+
T cell populations and thus independent of antigen spe-
cificity or persistence in HIV- controls (Figure 4b). In
contrast, the levels of activation seen in HIV+ donors
were significantly higher for CMV, EBV and VZV-spe-
cific responses and in some cases exceeded 20% of cyto-
kine producing cells. In Figure 4a, the activation levels
of single IL-2 or IFNγ-producing cells are shown along
with the levels for cells producing both cytokines in re-
sponse to all six antigens. In HIV+ donors, HIV-specific
cells producing IFNγ show higher activation levels than
cells producing IL-2 only, however activation levels did
not significantly differ between response profiles for the
other antigens. When we compared the activation levels
of the responses between HIV+ and HIV- donors, the
CMV-specific responses all displayed significantly higher
levels of activation in the HIV+ donors, however low num-
bers of responders by each cytokine combination meantthat activation levels for the other antigens did not reach
significance.
Remarkably, the TT-specific responses showed similar
low levels of activation in both HIV+ and HIV- donors.
Lastly, the mean T cell activation in HIV+ individuals
was highest for HIV-specific CD4+ T cells and was sig-
nificantly higher than the activation levels of CMV, HSV
and TT-specific CD4+ T cells (all p < 0.01).
Discussion
We have studied immune activation levels and cytokine
responses to a panel of persistent herpesviruses (CMV,
EBV, HSV and VZV) and a non-persistent vaccine anti-
gen (TT) in a cohort of patients with untreated chronic
HIV-1 infection and compared them to responses in
HIV-negative controls. While activated CD4+ T cells
displayed elevated levels of the inhibitory marker PD-1
in both HIV+ and HIV- individuals, the overall levels of
activated CD4+ T cells were elevated only in the setting
of HIV infection, as shown to be characteristic of chro-
nic HIV infection [3,13]. In HIV-negative controls, fre-
quencies of activated CD4+ T cells were very low and
independent of antigen specificity or persistence. In HIV+
individuals, HIV-specific CD4+ T cells displayed the
highest level of activation, followed by EBV, CMV, HSV,
VZV and TT-specific cells. This ‘hierarchy’ may correlate
with the level of persistence or the likelihood of reacti-
vation/re-encounter of the respective virus/antigen, al-
though this has not been formally addressed but may be
inferred from the differentiation profile of CD8+ T cells
Figure 4 Comparison of activation levels of antigen-specific populations between HIV+ and HIV- donors. Antigen-specific responses
(depicted in Figure 3) were assessed for expression of the activation markers CD38 and HLA-DR. (a) Activation levels for each combination of
cytokines are depicted for the five persistent viral antigens and one non-persistent bacterial antigen. (b) Average activation levels for all cells
responding to each antigen. The table below depicts the number of donors responding to each antigen by the three combinations of cytokines.
Unpaired 2-tailed t-tests compared activation levels between HIV+ and HIV- donors.
Smith et al. BMC Infectious Diseases 2013, 13:100 Page 6 of 9
http://www.biomedcentral.com/1471-2334/13/100specific for these viruses/antigens [30,31]. Moreover, res-
ponses to the persistent herpesviruses all demonstrated
higher activation levels in HIV+ individuals than HIV-, a
phenomenon not observed for responses to the non-
persistent antigen TT. These results are compatible with
our theory that persistent antigens contribute to chronic
immune activation in HIV-positive individuals. An alter-
native explanation for our findings may be that some of
our HIV+ patients may have been sufficiently immunode-
ficient for relevant herpesvirus reactivation. However, we
did not find clinical evidence for viral reactivations and
there was no correlation between total CD4-counts (or
percentages) and the level of immune activation.PD-1 expression has been found to be elevated in HIV
infection [14] and is linked to HIV disease stage [32].
We found higher percentages of PD-1 expressing cells in
our HIV+ donors, however the level of PD-1 expression
on CD38+HLA-DR+ cells was similar in both HIV+ and
HIV- donors, suggesting that CD38+HLA-DR+ cells may
share features in spite of HIV status. Recently, PD-1
expression on CD38+HLA-DR+ T cells has led to the
definition of a distinct subset of CD4+ T cells called de-
regulated effector memory (DEM) cells [33], however
the authors of this study did not evaluate the percentage
of PD-1 expression on the CD38+HLA-DR+ cells in their
HIV+ and HIV- cohorts. A study of the gene expression
Smith et al. BMC Infectious Diseases 2013, 13:100 Page 7 of 9
http://www.biomedcentral.com/1471-2334/13/100profiles of activated cells in HIV+ and HIV- donors showed
significant differences in activated cells in HIV-infected
and HIV negative donors [34], with activated cells from
HIV+ donors expressing many more cell cycle-associated
and interferon-stimulated genes than activated cells from
HIV negative donors [34].
We detected both IFNγ and IL-2 responses to our
panel of antigens. HIV- and CMV-specific responses were
dominated by IFNγ producing cells; a mixture of IFNγ
and IL-2 was found for EBV, HSV and VZV specific res-
ponses and the TT response was almost completely IL-2
mediated. The detection of IFNγ, and not IL-2, in res-
ponse to HIV and CMV is consistent with the observed
hierarchy of cytokine response loss in CD8+ T cells during
chronic HIV infection [35]. Studies of the maturation sta-
tus of antigen-specific CD4+ T cells have shown that
CMV-specific responses are more mature than both HIV
and TT-specific responses [19,23], and that CMV respon-
ses preferentially involve IFNγ production, while TT
responses are mainly IL-2 mediated [23]. The lack of IL-2
responses to CMV also fits with recent data showing that
CMV-specific CD4+ T cells produce little IL-2 but high
levels of the CCR5 chemokine MIP-1β [36]. Geldmacher
and colleagues showed that IL-2 producing cells are more
vulnerable to HIV infection in vivo and are therefore
deleted. Our data could be interpreted through this para-
digm, with maintenance of IFNγ-producing cells specific
for herpesviruses which are poor IL-2 producers, and the
TT-specific cells maintained to similar levels in HIV+ and
HIV- individuals potentially because although they pro-
duce IL-2, they are not activated and are therefore poor
targets for HIV replication.
The higher levels of activation seen in herpes-virus
specific cells, in contrast to the low activation levels seen
on TT-specific cells, suggests that these cells may be
more susceptible to bystander activation. Bystander acti-
vation is a phenomenon primarily described for CD8+ T
cells [24,37], but which has also been clearly demons-
trated to occur in CD4+ T cells [26,38]. Bystander activa-
tion occurs via the actions of cytokines, TLR ligands
and/or indirect mechanisms leading to a partial activa-
tion of T cells of varying specificities. However, it has yet
to be demonstrated in humans that bystander activation
alone is sufficient for the simultaneous up-regulation of
HLA-DR and CD38 in the absence of any TCR-media-
ted signals. A recent study from our group demonstrated
that the dynamics of responses to persistent herpes-
viruses, but not non-persisting antigens, closely mirrored
the HIV-specific response on HIV viral rebound [27].
This observation was linked to dendritic cell activation
and improved antigen presentation, and was dependent
on the presence of a low level of cognate antigen. Similar
observations have been made with CD8+ T cell respon-
ses, with simultaneous fluctuations of CMV and EBV-specific cells noted in persistent infection [39]. More-
over, primary HIV infection has been shown to cause
low-level activation of CD8+ T cells specific for CMV
and EBV (and influenza, although this is not a persistent
antigen) [40,41] and treating HIV-infected patients with
an anti-herpesvirus drug reduced CD8+ T cell activation
[42]. A study of patients with a variety of acute viral
infections demonstrated that all acute infections (includ-
ing dengue, hepatitis B and adenovirus) activated her-
pesvirus-specific CD8+ T cells but not influenza-specific
CD8+ T cells [29]. In this case, the authors suggest that
the action of IL-15 contributes to this selective activation
of herpesvirus-specific cells.
There are some limitations to the study presented here.
Due to current treatment guidelines most patients are
treated early with antiretroviral therapy, limiting the pa-
tients eligible for our study. In addition, a substantial
number of potential participants were excluded after pre-
screening by ELISpot since we were unable to detect
robust CD4+ T cell responses against the antigens of in-
terest. We analyzed IFNγ and IL-2 production, however
CD4+ T cells can also produce significant quantities of
TNFα, MIP-1β and IL-17, which could be assessed to give
a broader representation of CD4 responses. Finally, to cor-
roborate our findings, cells specific for non-persistent an-
tigens other than TT, such as influenza and adenovirus,
could be studied. We attempted to measure frequencies of
adenovirus-specific CD4+ T cell responses in a number of
HIV+ individuals in our cohort. In almost all patients,
however, these responses were below the detection limit.
CD4+ T cells co-expressing HLA-DR, CD38 and PD-1
have previously been characterized as DEM cells in chron-
ically infected Ugandans [33]. More detailed analysis of
the DEM cells demonstrated that HIV- and CMV-specific
responses were enriched amongst them, and that they
exhibited a diverse Vβ repertoire, suggesting that the po-
pulation is comprised of cells of diverse antigen specifi-
cities [33]. This study, along with the data presented here,
suggests that the CD4+CD38+HLA-DR+ population could
be considered a distinct population, sharing an elevated
level of PD-1 expression, lack of integrin β7, and as re-
cently demonstrated, an elevated expression of the HIV
co-receptor CCR5 [43]. This CD4+CD38+HLA-DR+ popu-
lation may represent cells specific for a variety of persist-
ent antigens receiving some level of TCR-dependent
triggering which are preferentially activated in the pre-
sence of inflammatory cytokines and TLR ligands, both
hallmarks of chronic HIV infection.
Conclusions
The data presented in this paper further characterize the
nature of activated CD4+ T cells in untreated HIV infec-
tion. We demonstrate the influence of antigen exposure
on susceptibility to activation, and show that CD4+ T cells
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those specific for non-persisting antigens. These observa-
tions suggest a mechanism contributing to the generalized
immune activation seen in HIV infection, which is an im-
portant step towards developing strategies to limit the
pathological activation linked to HIV disease progression.
Additional files
Additional file 1: Figure S1. Gating for PD-1 and β7 expression.
Fluorescence minus one (FMO) gating shown on CD4+ lymphocytes. The
left plot shows the FMO control for PD-1 PE-Cy7, the middle plot shows
the FMO control for β7 FITC and the right plot shows the resulting gates
on a sample containing all antibodies. All control samples were derived
from the same donor and analysed together.
Additional file 2: Figure S2. Intracellular cytokine staining procedure
has minimal effect on activation levels. The expression of CD38 and HLA-
DR induced by the intracellular cytokine assay was assessed by
comparing activation levels in the DMSO (negative) and SEB (positive)
controls. Here the fold change demonstrated between DMSO and SEB is
graphed against the percentage of activated CD4+ T cells in the DMSO
control. There is no significant correlation (r = −0.18, p = 0.33). Donors
with higher baseline levels of activation did not show any greater
increase in activation through the assay than those with lower baseline
levels of activation. Overall, the activation induced by the assay was no
more than one times the background level.
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